Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations
| Brand name | METFORMIN HYDROCHLORIDE |
| Generic name | METFORMIN HYDROCHLORIDE |
| Active ingredient(s) | METFORMIN HYDROCHLORIDE |
| Distributed by / for | BAYSHORE PHARMACEUTICALS |
| NDC | 76385-129-01 |
| Full product label | Metformin Hydrochloride Extended-Release Tablets USP, 750 mg 100 Tablets Rx Only Manufactured by: Beximco Pharmaceuticals, LTD. 126, Kathaldia, Tongi, Gazipur, 1711, Bangladesh NDC 76385-129-01 |
| Recalling firm | BAYSHORE PHARMACEUTICALS |
| Distribution | nationwide |
| Quantity | 3984 bottles |
| Recall initiated | 2020-08-19 |
| Report date | 2020-09-02 |
| Recall completed | 2021-04-26 |
| Recall number | D-1544-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Short Hills NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗